RPRX Stock: Royalty Pharma plc Stock Price, Analysis & Insights
Get live RPRX stock price $54.66, comprehensive Royalty Pharma plc stock analysis, charts, news, and expert forecast. Real-time RPRX stock data and investment insights.
Loading chart data...
Royalty Pharma plc (RPRX) Overview
Royalty Pharma plc (RPRX) is a publicly traded company in the Healthcare sector , specifically within the Biotechnology industry . As of the latest trading session, RPRX trades at $54.66 with a market capitalization of 23.51B . Over the past 52 weeks, RPRX has traded between $33.59 and $56.50 , with the current price positioned at approximately 92% of this range . The stock currently trades at ...
Key Takeaways
- Operates in the Healthcare sector (Biotechnology)
- Market cap: 23.51B
- Current price: $54.66
- 52-week range: $33.59 - $56.50
- P/E ratio: 28.77
Investment Score
A systematic tri-factor framework that integrates valuation, business quality, and market momentum into one investment signal. This helps investors triage opportunities faster, while surfacing risk regimes that may require tighter position sizing or deeper due diligence.
Score unavailable for this asset.
0-39
Defensive posture
40-54
Mixed / wait for confirmation
55-69
Constructive setup
70-100
Attractive zone
Total Score
Value
Cheapness vs fundamentals and cash generation
Quality
Durability of profitability and balance sheet
Momentum
Price trend strength and persistence
Company Overview
Royalty Pharma plc, headquartered in New York City and founded in 1996, operates within the United States as a key player in the biopharmaceutical industry. The company primarily focuses on the acquisition of royalties from biopharmaceutical products...
Company Information
- CEO
- Pablo Legorreta
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 75
Contact Information
- Address
- 110 East 59th Street
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Growth-oriented company with premium valuation (P/E: 28.8)
✓ Lower volatility stock (Beta: 0.42) may provide portfolio stability
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Royalty Pharma plc shareholders
- ⚠Market volatility can significantly impact stock price, especially for mid-cap stocks
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Royalty Pharma plc
- ⚠Investors should consider how Royalty Pharma plc fits within their overall portfolio allocation
Market Cap
23.51B
P/E Ratio (TTM)
28.77
Beta
0.42
Data Sources & Methodology
Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.
Related Stocks
Compare RPRX with peer companies:
- Price
- $53.07
- Market cap
- 13.34B
- Price
- $22.33
- Market cap
- 11.99B
- Price
- $24.59
- Market cap
- 15.10B
- Price
- $76.01
- Market cap
- 16.97B
- Price
- $105.53
- Market cap
- 21.08B
- Price
- $28.63
- Market cap
- 20.59B
- Price
- $12.64
- Market cap
- 9.80B
- Price
- $31.02
- Market cap
- 13.17B
- Price
- $162.78
- Market cap
- 14.02B
- Price
- $540.72
- Market cap
- 22.95B
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.